ABSTRACT

Introduction

Despite new treatment options, the long-term prognosis of recurrent or inoperable gastric cancer remains poor. Antibody–drug conjugates (ADCs) are a new class of drugs and have shown promising results in clinical trials.

Areas covered

This review focuses on recent clinical findings and development of ADCs for gastric cancer, and summarizes the relevant resistance mechanisms or future directions of ADCs.

Expert opinion

Novel HER2-ADCs have led to breakthrough results for HER2⁺ gastric cancer; however, several questions remain, especially in clinical settings. Translational research to elucidate ADCs’ mechanisms of action or resistance will lead to more sophisticated use of ADCs and combination strategies.

中文翻译：

---

用于治疗胃癌的抗体-药物偶联物

摘要

介绍

尽管有新的治疗选择，复发或不能手术的胃癌的长期预后仍然很差。抗体-药物偶联物 (ADCs) 是一类新型药物，在临床试验中显示出可喜的结果。

涵盖的领域

本综述重点介绍胃癌 ADCs 的最新临床发现和发展，并总结 ADCs 的相关耐药机制或未来发展方向。

专家意见

新型 HER2-ADC 为HER2 ⁺胃癌带来了突破性的结果；然而，仍然存在几个问题，尤其是在临床环境中。阐明 ADC 的作用或耐药机制的转化研究将导致更复杂的 ADC 使用和组合策略。